Expected...In Q2 CY 2016 Teva and Mesoblast to provide updated...

Expected...In Q2 CY 2016 Teva and Mesoblast to provide updated timelines for completion of current reduced Phase 3 Trial, regulatory submissions, and overall program completion... .another version....During Q2 CY 2016: – European sites will be initiated for current Phase 3 trial – Updated timelines will be provided for completion of the current Phase 3 trial, FDA and EMA regulatory submissions, and overall program completion, including a confirmatory trial............Also .....The main candidate of licensing is MPC-06-ID for chronic low back pain (CLBP), as a result of degenerative disc disease. While not contained in the company’s releases, the clear impression from the presentation was that a deal for MPC-06-ID would be done this quarter or next (Q1 FY17)...........SI words were " in a short term"..To me the short term is up to 3-4 weeks thats a guess ..There is much happening with many apps .nothing would surprise ! V